Gilder Gagnon Howe & Co’s Vaxcyte PCVX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$992K	Sell	17,064 -111	-0.6%	-$6.03K	0.01%	242
2026 Q1	$998K	Buy	17,175 +1,066	+7%	+$57.9K	0.01%	220
2025 Q4	$743K	Sell	16,109 -32	-0.2%	-$1.43K	0.01%	225
2025 Q3	$581K	Sell	16,141 -144	-0.9%	-$4.77K	0.01%	235
2025 Q2	$529K	Sell	16,285 -74	-0.5%	-$2.43K	0.01%	220
2025 Q1	$618K	Sell	16,359 -191	-1%	-$15.3K	0.01%	201
2024 Q4	$1.35M	Buy	16,550 +42	+0.3%	+$4.17K	0.01%	197
2024 Q3	$1.89M	Sell	16,508 -323	-2%	-$29.1K	0.02%	187
2024 Q2	$1.27M	Sell	16,831 -247	-1%	-$16.8K	0.02%	192
2024 Q1	$1.17M	Sell	17,078 -23	-0.1%	-$1.59K	0.01%	207
2023 Q4	$1.07M	Sell	17,101 -5	-0%	-$260	0.01%	203
2023 Q3	$872K	Buy	17,106 +84	+0.5%	+$4.14K	0.01%	214
2023 Q2	$850K	Buy	17,022 +3,454	+25%	+$164K	0.01%	233
2023 Q1	$509K	Sell	13,568 -276	-2%	-$11.7K	0.01%	220
2022 Q4	$664K	Buy	+13,844	New	+$543K	0.01%	205

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Gilder Gagnon Howe & Co's PCVX Position: Q2 2026 in Review

Gilder Gagnon Howe & Co reduced its Vaxcyte (PCVX) stake by 0.65% in Q2 2026, selling an estimated $6.03K and leaving 17,064 shares worth $992K. The position accounts for 0.01% of the portfolio, ranked #242.

Gilder Gagnon Howe & Co first reported a position in PCVX in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.89M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Gilder Gagnon Howe & Co held 17,064 shares of Vaxcyte worth $992K as of Q2 2026.
Gilder Gagnon Howe & Co sold 111 Vaxcyte shares in Q2 2026, an estimated $6.03K.
Vaxcyte made up 0.01% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #242 holding.
Gilder Gagnon Howe & Co first reported a position in Vaxcyte in Q4 2022 and has held it in 15 quarters since.
Gilder Gagnon Howe & Co's Vaxcyte position peaked at $1.89M in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.